Nagai, S
A plausible scenario, then, looks like this: Phase 3 primary completion in late 2025, NDA submission in the second half of 2025, FDA filing acceptance and review initiation in early 2026, and a PDUFA (Prescription Drug User Fee Act) action date likely in mid to late 2026
"If a drug that aids in weight loss has FDA approval to treat another condition that the patient has, their doctor can prescribe it for that condition and it can potentially be covered by their Part D plan," Louise Norris, health policy analyst for MedicareResources.org, told Newsweek
GenScript Ni-Charged MagBeads and Glutathione MagBeads provide simple, rapid and reliable methods for micro-scale purification of His- and GST-tagged fusion proteins from crude cell lysate prepared from bacteria, yeast or mammalian cell culture
Studies show that early intervention with GLP-1 medications produces better long-term results, making the immediate access provided by cash pay providers clinically valuable (Martinez et al., Obesity Medicine, 2024)
Community protocols then increase to 0.5 mg 3x weekly (1.5 mg total weekly) when well-tolerated